Table 5.

Serum markers of insulin resistance and PPAR╬│ activation ┬▒ rosiglitazone therapy

TimeSubjects (n)Mean (SD)P
Adiponectin01716.39 (7.54)<0.001
11729.69 (10.12)
21716.87 (7.13)
C-peptide0171.51 (1.11)0.014
1171.28 (0.93)
2172.65 (1.96)
Glucose01763.09 (17.24)0.019
11674.09 (18.28)
21777.90 (12.74)
IGF-I017161.48 (45.37)0.905
117161.28 (49.89)
217167.35 (39.42)
IGFBP30172,154.49 (570.04)0.976
1172,142.23 (425.14)
2172,178.38 (448.94)
IL-60134.66 (5.57)0.864
1145.76 (7.74)
2134.70 (3.81)
Insulin0167.15 (4.61)0.005
1174.09 (2.50)
2178.83 (4.80)
Leptin01714.41 (6.95)0.569
11613.06 (5.73)
21615.43 (6.08)
MMP-9017842.41 737.41)0.609
117652.30 (530.25)
217914.09 (1,018.62)
QUICKI0163.32 (0.70)0.004
1173.93 (0.85)
2173.14 (0.43)
  • NOTE: Serum samples were obtained at baseline (time 0), last day of drug (time 1), and 30 d after the last dose (time 2).

    Abbreviations: IGFBP3, IGF binding protein 3; IL-6, interleukin-6; MMP-9, matrix metalloproteinase 9.